BCYC

SEC source: 0001209191-21-048919 · doc4.xml · nonDerivative · entry 2

Kalowski Lee · CIK 0001618273 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,504

F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.73 to $31.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5).

SEC source: 0001209191-21-048919 · doc4.xml · nonDerivative · entry 1

Kalowski Lee · CIK 0001618273 · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.39511 to GBP 1.00 as of July 29, 2021.

SEC source: 0001209191-21-048348 · doc4.xml · derivative · entry 6

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,370

Underlying: Ordinary Shares · 100 shares

Expires 2029-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001209191-21-048348 · doc4.xml · nonDerivative · entry 4

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,085

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001209191-21-048348 · doc4.xml · nonDerivative · entry 3

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,185

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-048348 · doc4.xml · derivative · entry 5

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,470

Underlying: Ordinary Shares · 4,782 shares

Expires 2029-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001209191-21-048348 · doc4.xml · nonDerivative · entry 2

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,085

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-048348 · doc4.xml · nonDerivative · entry 1

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,867

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046996 · doc4.xml · derivative · entry 6

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,252

Underlying: Ordinary Shares · 609 shares

Expires 2029-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001209191-21-046996 · doc4.xml · nonDerivative · entry 4

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,085

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001209191-21-046996 · doc4.xml · nonDerivative · entry 3

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,694

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046996 · doc4.xml · derivative · entry 5

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,861

Underlying: Ordinary Shares · 21,970 shares

Expires 2029-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001209191-21-046996 · doc4.xml · nonDerivative · entry 2

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,085

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-046996 · doc4.xml · nonDerivative · entry 1

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046698 · doc4.xml · derivative · entry 14

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 368,831

Underlying: Ordinary Shares · 8,331 shares

Expires 2029-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 11

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,085

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 10

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,138

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.16 to $35.11 inclusive.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 9

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,222

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.15 to $34.12 inclusive.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 8

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 256,908

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.15 to $33.14 inclusive.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 7

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-028546 · doc4.xml · nonDerivative · entry 4

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P.

Disclosed balance after: 38,708

F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F4 · ownership.nature: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC source: 0000899243-21-028546 · doc4.xml · nonDerivative · entry 2

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V, L.P.

Disclosed balance after: 1,831,671

F1 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F2 · ownership.nature: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC source: 0001209191-21-046997 · doc4.xml · nonDerivative · entry 1

Keen Nicholas · CIK 0001776881 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,321

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-21-028984 · doc4a.xml · nonDerivative · entry 4

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P.

Disclosed balance after: 38,708

F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F4 · ownership.nature: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC source: 0000899243-21-028984 · doc4a.xml · nonDerivative · entry 2

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V, L.P.

Disclosed balance after: 1,831,671

F1 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F2 · ownership.nature: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC source: 0001209191-21-046698 · doc4.xml · derivative · entry 13

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,162

Underlying: Ordinary Shares · 35,446 shares

Expires 2029-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 6

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,219

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 5

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,413

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50 inclusive.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 4

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,201

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.98 inclusive.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 3

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 15

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,764

Underlying: Ordinary Shares · 13,019 shares

Expires 2030-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on February 21, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter.

SEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 14

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,750

Underlying: Ordinary Shares · 19,256 shares

Expires 2030-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter.

SEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 13

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,660

Underlying: Ordinary Shares · 40,426 shares

Expires 2029-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 26, 2020, and the remaining shall vest in 36 equal monthly installments.

SEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 9

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50 inclusive.

SEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 8

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,121

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.99 inclusive.

SEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 7

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,701

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 6

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 5

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-028546 · doc4.xml · nonDerivative · entry 3

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P.

Disclosed balance after: 39,625

F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F4 · ownership.nature: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC source: 0000899243-21-028546 · doc4.xml · nonDerivative · entry 1

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V, L.P.

Disclosed balance after: 1,875,049

F1 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F2 · ownership.nature: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC source: 0000899243-21-028984 · doc4a.xml · nonDerivative · entry 3

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P.

Disclosed balance after: 39,625

F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F4 · ownership.nature: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC source: 0000899243-21-028984 · doc4a.xml · nonDerivative · entry 1

BINGHAM KATE · CIK 0001185040 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Life Sciences Fund V, L.P.

Disclosed balance after: 1,875,049

F1 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F2 · ownership.nature: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC source: 0001209191-21-046698 · doc4.xml · derivative · entry 12

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,608

Underlying: Ordinary Shares · 1,936 shares

Expires 2029-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 2

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,734

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7).

SEC source: 0001209191-21-046698 · doc4.xml · nonDerivative · entry 1

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 256,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 12

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,783

Underlying: Ordinary Shares · 974 shares

Expires 2030-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on February 21, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter.

SEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 11

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,006

Underlying: Ordinary Shares · 1,723 shares

Expires 2030-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter.

SEC source: 0001209191-21-046700 · doc4.xml · derivative · entry 10

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,086

Underlying: Ordinary Shares · 4,331 shares

Expires 2029-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 26, 2020, and the remaining shall vest in 36 equal monthly installments.

SEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 4

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).

SEC source: 0001209191-21-046700 · doc4.xml · nonDerivative · entry 3

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,028

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.